To improve life during and beyond sedation
Sedana Medical is a pioneer medtech and pharmaceutical company dedicated to making inhaled sedation a standard therapy in intensive care.More about us
Bringing inhaled sedation to intensive care
We are proud to introduce inhaled sedation to intensive care, a paradigm shift in the care of critically ill patients.
Through the results obtained in the pivotal study with Sedaconda (isoflurane) and Sedaconda ACD*, we have laid the foundation for inhaled sedation in intensive care.
By this, we have also taken a major step closer to our vision – to make inhaled sedation a standard therapy in intensive care.
*formerly known as AnaConDa
Science & Clinical Research
We pave the way for a paradigm shift in sedation in intensive care through knowledge sharing and clinical research.
Sedasource is an online resource for healthcare professionals, providing scientific and clinical material on the sedation of critically ill patients.
Our research aims at a greater understanding of and increased knowledge about inhaled sedation, leading to medical advances for the benefit of patients in intensive care.
We also believe in working in partnerships – through various initiatives and research projects – that can lead to continued development and meaningful improvement for both patients and the healthcare system.
Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031
Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has iss…
Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study…